Papa Alfonso, Di Dato Maria Teresa, Buonavolonta Pietro, Saracco Elisabetta, Salzano Anna Maria, Casale Beniamino
Pain Department, Monaldi Hospital Napoli, Naples, Italy.
IPAS Moleculat Immunological Therapy AO Ospedali dei Colli- Monaldi Hospital Napoli, Naples, Italy.
Anesth Pain Med. 2020 Aug 1;10(4):e104151. doi: 10.5812/aapm.104151. eCollection 2020 Aug.
In the last months of 2019, the advent of a new virus called SARS-CoV-2 caused the spread of a pandemic disease, COVID-19, that has afflicted patients with chronic pain.
We describe a COVID-19 patient recently implanted with a spinal cord stimulator for FBSS, treated with Tocilizumab for cytokine storm complicating SARS-COV-2 infection. This patient developed a delayed hyperimmune reaction, causing an inflammatory reaction in the surgical pocket site, well treated with total remission. The total resolution of this local reaction occurred after the resolution of systemic COVID-19 infection by Tocilizumab.
We discuss the balance between damage-associated molecular patterns (DAMPs) and pathogen-recognition receptors (PRRs), and the putative role of polymorphism in the IL-6/174 position of the promoter region.
2019年的最后几个月,一种名为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新型病毒出现,导致了一场大流行病——冠状病毒病2019(COVID-19)的传播,该病困扰着慢性疼痛患者。
我们描述了一名近期因Failed Back Surgery Syndrome(FBSS)植入脊髓刺激器的COVID-19患者,该患者因SARS-CoV-2感染并发细胞因子风暴而接受托珠单抗治疗。该患者发生了延迟性超敏反应,导致手术切口部位出现炎症反应,经治疗完全缓解。在托珠单抗使全身性COVID-19感染消退后,这种局部反应完全消退。
我们讨论了损伤相关分子模式(DAMPs)与病原体识别受体(PRRs)之间的平衡,以及启动子区域白细胞介素-6(IL-6)/174位点多态性的假定作用。